Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.

Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR.

BMC Urol. 2019 Sep 9;19(1):84. doi: 10.1186/s12894-019-0515-z.

2.

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.

O'Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, Ost P, van Oort I, Tombal B.

Eur Urol Oncol. 2019 Mar 25. pii: S2588-9311(19)30031-8. doi: 10.1016/j.euo.2019.02.007. [Epub ahead of print] Review.

PMID:
31411991
3.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Aug 9. pii: S1470-2045(19)30412-7. doi: 10.1016/S1470-2045(19)30412-7. [Epub ahead of print]

PMID:
31405822
4.

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).

Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T, Sakk SGFCCR.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1099. doi: 10.3390/cancers11081099.

5.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ.

Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14.

6.

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S; Swiss Group of Clinical Cancer Research (SAKK).

Br J Cancer. 2019 May;120(10):968-974. doi: 10.1038/s41416-019-0447-0. Epub 2019 Apr 16.

7.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G.

J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.

PMID:
30875280
8.

Reply to V. Murthy et al.

Cathomas R, Beyer J.

J Clin Oncol. 2019 Apr 10;37(11):938-939. doi: 10.1200/JCO.18.02289. Epub 2019 Feb 27. No abstract available.

PMID:
30811288
9.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.

Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A.

J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5.

10.

Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.

Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R.

Clin Genitourin Cancer. 2019 Apr;17(2):e323-e328. doi: 10.1016/j.clgc.2018.12.009. Epub 2019 Jan 2.

PMID:
30686756
11.

Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the link.

Vögelin M, Cathomas R, Kamber N, Fehr T.

BMJ Case Rep. 2019 Jan 18;12(1). pii: bcr-2018-227068. doi: 10.1136/bcr-2018-227068.

PMID:
30661045
12.

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry.

Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C, Haugnes HS, Hentrich M, Fankhauser C, Gillessen S, Beyer J.

J Clin Oncol. 2018 Oct 4:JCO1800210. doi: 10.1200/JCO.18.00210. [Epub ahead of print]

13.

[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].

Omlin A, Spahn M, Beyer J, Eberli D, Gillessen S, Jochum W, Kueng M, Nitzsche E, Rentsch CA, Roggero E, Schmid HP, Stenner F, Templeton AJ, Wild D, Wyler S, Zwahlen D, Cathomas R.

Praxis (Bern 1994). 2018 Sep;107(19):1043-1051. doi: 10.1024/1661-8157/a003054. Review. German. No abstract available.

PMID:
30227804
14.

Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).

Rothermundt C, Thurneisen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild SI, Seifert B, Terbuch A, Grassmugg T, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Gillessen S.

Swiss Med Wkly. 2018 Aug 29;148:w14674. doi: 10.4414/smw.2018.14674. eCollection 2018 Aug 27. No abstract available.

15.

Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).

Rothermundt C, Thurneysen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild S, Seifert B, Terbuch A, Grassmugg T, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Gillessen S.

Swiss Med Wkly. 2018 Jul 24;148:w14640. doi: 10.4414/smw.2018.14640. eCollection 2018. Erratum in: Swiss Med Wkly. 2018 Aug 29;148:w14674. Erratum.

16.

Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I.

Fehr M, Maranta AF, Reichegger H, Gillessen S, Cathomas R.

ESMO Open. 2018 Mar 8;3(3):e000320. doi: 10.1136/esmoopen-2018-000320. eCollection 2018.

17.

Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.

Sandmeier N, Rothschild SI, Rothermundt C, Cathomas R, Schardt J, Berthold D, von Burg P, Müller B, Beyer J, Vogt DR, Stenner F.

Clin Genitourin Cancer. 2018 Aug;16(4):e711-e718. doi: 10.1016/j.clgc.2018.01.002. Epub 2018 Feb 2.

PMID:
29503245
18.

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.

Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner S, Pless M, Stenner F, Rothschild SI.

J Cancer. 2018 Jan 1;9(2):250-255. doi: 10.7150/jca.22318. eCollection 2018.

19.

Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.

Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.

J Nucl Med. 2018 Jun;59(6):915-921. doi: 10.2967/jnumed.117.199760. Epub 2017 Nov 30.

20.

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30275-6. doi: 10.1016/j.clgc.2017.08.020. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center